Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$2.79
-$0.25(-2.12%)
At close: 4:00 PM EST
$2.79
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.15 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)731.09K
Market Cap
$122.02M
Enterprise Value$143.62
Total Cash (Recent Filing)$93.53M
Total Debt (Recent Filing)$33.39M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 10, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.63
Shares Outstanding47,293,064
10 Day Avg. Volume482,053
30 Day Avg. Volume731,087
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside7.53% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$143.81M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables EcosystemQuanterix’s installed instruments can create recurring consumables and service revenue, supporting customer retention and revenue durability. As the installed base expands, ongoing assay usage may improve visibility and operating leverage beyond one-time instrument sales.
Akoya Synergies And Margin RecoveryCompleted integration and realized cost synergies provide a structural opportunity to simplify operations and reduce the combined cost base. The 600-basis-point improvement in non-GAAP gross margin also supports a path toward better economics if revenue execution stabilizes.
Diagnostics Reimbursement ProgressReimbursement and payer-coverage milestones can improve adoption of LucentAD Complete by reducing customer payment uncertainty. Greater clinical access would support a longer-term shift toward diagnostics revenue and strengthen Quanterix’s position in blood-based neurodegeneration testing.
Bears Say
Lower Revenue Outlook And Delayed Break-evenThe guidance reset indicates that commercial execution and demand recovery are taking longer than expected. Lower revenue reduces near-term scale benefits, while the delayed break-even target extends dependence on cash resources and increases the time required to prove the integrated strategy.
Severe Losses And Accelerating Cash BurnPersistent operating losses and accelerating cash use weaken financial flexibility and can force management to prioritize funding over growth investment. Although leverage is low, continued burn may require cost reductions, additional capital or slower execution before sustainable profitability is reached.
Broad Segment And Consumables WeaknessWeakness across multiple platforms and customer groups suggests the problem is broader than a single product or market. Lower instrument sales and consumable pull-through can impair the recurring-revenue engine, delay recovery of fixed costs and make the planned diagnostics-led transition harder to execute.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.15 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $122.02M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Nov 10, 2026 which is in 65 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Aug 10, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.63.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.43.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,293,064 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went down -39.95%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (7.53% Upside)
$3.00 (7.53% Upside)
Blogger Sentiment
Neutral
QTRX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $296.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Company Deck
QTRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear near-term challenges and a meaningful guide reduction against several operational and strategic positives. Management reported a sizable Q2 revenue shortfall and cut full-year revenue guidance materially, delaying cash-flow break-even to 2027, which are significant negatives. Offsetting this, the company preserved cash, completed Akoya integration and $85M of synergies, achieved substantial non-GAAP gross margin improvement, showed sequential bookings momentum (book-to-bill 1:1), secured important reimbursements and coverage wins for its LucentAD diagnostic (CMS pricing and Anthem coverage), launched new assays and Spatial products, and added experienced commercial and diagnostics leadership while reorganizing sales for improved execution. Overall, positives and active corrective actions are substantial but are currently counterbalanced by the material revenue shortfall, segment weakness, and near-term financial impacts.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$3.00
▲(7.53% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
6.82% Insiders
19.57% Mutual Funds
25.43% Other Institutional Investors
37.05% Public Companies and
Individual Investors